Last updated on July 2019

A Phase 1 Multi-Center Open-Label Dose-Escalation Safety Pharmacokinetic and Pharmacodynamic Study of Minnelide Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors


Brief description of study

A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of MinnelideCapsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors

Clinical Study Identifier: NCT03129139

Find a site near you

Start Over

Mayo Clinic Arizona

Phoenix, AZ United States
  Connect »

HonorHealth Research Institute

Scottsdale, AZ United States
  Connect »

Cedars-Sinai Medical Center

Los Angeles, CA United States
  Connect »

Mayo Clinic

Jacksonville, FL United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »